BOSTON IMMUNE TECHNOLOGIES & THERAPEUTICS
BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.
BOSTON IMMUNE TECHNOLOGIES & THERAPEUTICS
Industry:
Biotechnology Therapeutics
Founded:
2011-01-01
Address:
Winchester, Virginia, United States
Country:
United States
Website Url:
http://www.bostonimmunetech.com
Total Employee:
1+
Status:
Active
Total Funding:
10 M USD
Technology used in webpage:
SPF Content Delivery Network Font Awesome Microsoft Exchange Online Office 365 Mail IPv6 BootstrapCDN Cloudflare Hosting Cloudflare DNS
Current Advisors List
Current Employees Featured
Founder
Investors List
BeiGene
BeiGene investment in Series A - Boston Immune Technologies & Therapeutics
Hatteras Venture Partners
Hatteras Venture Partners investment in Series A - Boston Immune Technologies & Therapeutics
Official Site Inspections
http://www.bostonimmunetech.com Semrush global rank: 5.42 M Semrush visits lastest month: 1.56 K
- Host name: 104.21.12.125
- IP address: 104.21.12.125
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Boston Immune Technologies & Therapeutics"
Boston Immune Technologies and Therapeutics | LinkedIn
Boston Immune Technologies and Therapeutics Biotechnology Research Boston, …See details»
Boston Immune Technologies & Therapeutics - Crunchbase
View contacts for Boston Immune Technologies & Therapeutics to access new leads and …See details»
BITT | Boston Immune Technologies & Therapeutics
Order cheap Hydrochlorothiazide High Blood Pressure cheap no prescription Discuss the risks …See details»
Boston Immune Technologies and Therapeutics, Inc.
Website: https://www.bostonimmunetech.com. Develops a proprietary discovery platform for …See details»
Boston Immune Technologies & Therapeutics, Inc.: Drug pipelines ...
Jun 21, 2023 Explore Boston Immune Technologies & Therapeutics, Inc. with its drug …See details»
Boston Immune Technologies & Therapeutics Inc · Boston Immune ...
BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC. (doing business as …See details»
Boston Immune Technologies & Therapeutics - Craft
Boston Immune Technologies & Therapeutics $10 m in total funding,. See insights on Boston …See details»
Boston Immune Technologies and Therapeutics - ZoomInfo
Aug 18, 2023 BITT To Present Update on CD40 Program at AAI 2023 BOSTON--(BUSINESS …See details»
Media | BITT - Boston Immune Tech
August 16, 2024 BITT Announced CD40 Otsuka Research and Exclusivity Agreement and …See details»
Boston Immune Technologies and Therapeutics, Inc.
Oct 29, 2017 www.bostonimmunetech.com : disclaimers Any reproduction or further …See details»
BITT Announced CD40 Otsuka Research and Exclusivity Agreement …
Aug 16, 2024 BITT has begun clinical trials for BIR2101, its lead candidate, which is a …See details»
Boston Immune Technologies and Therapeutics and BeiGene Enter …
Feb 17, 2021 Exclusive license for Asia (ex-Japan), Australia and New Zealand; Parties plan …See details»
BITT Announced CD40 Otsuka Research and Exclusivity Agreement …
Aug 16, 2024 Learn more at: www.bostonimmunetech.com. Contacts. Karl Schmieder …See details»
BITT Announces NIH SBIR Award and New Board Member
Dec 13, 2021 BITT has received a SBIR grant from the National Cancer Institute at the US …See details»
BITT Announces NIH Award for Advancement of Anti-CD40 Antibody
Aug 31, 2023 Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical-stage …See details»
Boston Immune Technologies and Therapeutics Raises $10M …
Mar 17, 2021 For more information, visit our website at www.bostonimmunetech.com. …See details»
Science | BITT - Boston Immune Tech
Science. would like to process and share personal data (e.g., mobile ad id) and data about …See details»
Selexis and Boston Immune Technologies and Therapeutics (BITT) …
Mar 9, 2021 GENEVA & BOSTON--(BUSINESS WIRE)--Mar 9, 2021-- Selexis SA and …See details»
Boston Immune Technologies and Therapeutics and BeiGene Enter …
Feb 17, 2021 For more information, visit our website at www.bostonimmunetech.com. About …See details»
Russell LaMontagne - President & Chief Executive Officer at …
Oct 19, 2024 Russell LaMontagne contact details: Email address: …See details»